Using this data, Everist created the world’s only molecular diagnostic test, OncoDefender-CRC, which can accurately identify tumors at high risk for recurrence among early-stage colon and rectal cancers. The test became commercially available in November, and the company has received physician requests for more than 1,000 specimen collection kits. Sanford Health Plan, which provides insurance in South Dakota, North Dakota, Iowa, Minnesota and Nebraska, has established a policy that will reimburse members for the test beginning in Jan. 2012.
Related Articles on Colorectal Cancer Screening:
Water Infusion for Cecal Intubation Increases Patient Tolerance, but not Intubation in Unsedated Colonoscopy
AGA Releases New Standards for Performing CT Colonography
Colonoscopy Best for Monitoring Mucosal Healing in Patients With Ulcerative Colitis
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
